Target intelligence / Profile preview

Spindle and kinetochore-associated complex subunit 2 (SKA2)

Target
SKA2
Molecular classification
Other (mitotic spindle-associated protein), Microtubule-binding protein
01

Overview

Spindle and kinetochore-associated complex subunit 2 (SKA2) is a small, highly conserved protein encoded by the SKA2 gene in humans, which forms part of the SKA complex (with SKA1 and SKA3). This complex is essential for proper chromosome segregation during mitosis, specifically facilitating the timely onset of anaphase by enabling the stable attachment of spindle microtubules to kinetochores. Beyond its core mitotic role, SKA2 interacts directly with the glucocorticoid receptor (GR), enhancing its nuclear translocation in neurons and peripheral tissues, which has implications for regulation of the hypothalamic–pituitary–adrenal (HPA) axis, stress response, and psychiatric disease mechanisms. SKA2 also modulates secretory autophagy in the brain, intersecting neuroinflammatory pathways linked to neurodegeneration. Clinically, altered SKA2 DNA methylation is studied as a potential biomarker for suicide risk and post-traumatic stress disorder, and its coordinated expression with PRR11 has a proposed role in lung cancer proliferation[1][2][4][7].

Other names
FAM33AProtein FAM33Aspindle and KT (kinetochore) associated 2spindle and kinetochore-associated protein 2family with sequence similarity 33, member AFLJ12758
02

Mechanism of action

Not drug-targeted; mechanistically, SKA2 enhances glucocorticoid receptor signaling through promoting FKBP4 interaction and modulates nuclear translocation of the glucocorticoid receptor[2].

03

Biological functions

Cell cycle regulationChromosome segregation during mitosisAttachment of mitotic spindle microtubules to kinetochoreRegulation of microtubule polymerization/depolymerizationRegulation of stress-related glucocorticoid receptor signalingRegulation of secretory autophagy
04

Disease associations

Cancer (notably lung cancer)Psychiatric disorders (suicidal tendencies, post-traumatic stress disorder, bipolar disorder)Neurodegenerative diseases (Alzheimer's disease; via secretory autophagy regulation)
05

Safety considerations

Not a therapeutic target; safety/therapeutic challenges are not established because no drugs target SKA2 directly.Potential concern: as a prognostic biomarker for psychiatric risk, interpretation or misapplication of methylation data could impact clinical decision-making[1].
06

Biomarkers

SKA2 DNA methylation (for suicidal behavior and psychiatric disorder risk)SKA2 gene expression (potential prognostic marker for lung cancer)

Beyond the preview

Go deeper on Spindle and kinetochore-associated complex subunit 2 (SKA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spindle and kinetochore-associated complex subunit 2 (SKA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call